Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

3.80% 3.97% 5.34% 9.03%
Piotroski F-Score
5 7 7 9
ROA
2.96% 3.12% 4.22% 7.07%
ROIC
3.24% 3.48% 4.63% 7.70%
Return on Tangible Assets
11.06% 11.09% 14.27% 22.38%
Average Days of Receivables
55.17 55.43 64.68 65.06
Free Cash Flow per Share
1.44 1.43 1.72 1.69
Free Cash Flow
224.06 223.02 269.60 263.22
Other line items

Show all line items

Columns are period end dates